OBSV - オブスイヴァ (ObsEva SA) オブスイヴァ

 OBSVのチャート


 OBSVの企業情報

symbol OBSV
会社名 ObsEva SA (オブスイヴァ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109) an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban (OBE001) an oral oxytocin receptor antagonist undergoing phase 3 of clinical trials with the potential to inhibit uterine contractions at the time of embryo transfer thereby enhancing embryo implantation during assisted reproductive technologies (ART) and OBE022 an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor (phase 2a of clinical trials).   オブスイヴァはスイスのバイオ医薬品企業。臨床段階で、女性の不妊・生殖医療に関する治療薬の開発・商業化に従事。不妊・生殖医療において、治療の選択肢が限られている、またはニ―ズに合っていない個人の状況に適した治療方法を開発する。不妊、困難な妊娠、新生児の健康状態、その他の生活の質に影響を与える疾患に焦点を当てる。本社はジュネ―ブ。   ObsEva SA engages in the research and development of therapeutic treatments for woman's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.
本社所在地 Chemin des Aulx 12 1228 Plan-les-Ouates Geneva CHE
代表者氏名 Frank Verwiel フランク・ヴェルヴィエル
代表者役職名 Independent Chairman of the Board
電話番号 +41 22-552-3840
設立年月日 41214
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 39人
url www.obseva.com
nasdaq_url https://www.nasdaq.com/symbol/obsv
adr_tso
EBITDA EBITDA(百万ドル) -71.87900
終値(lastsale) 16.87
時価総額(marketcap) 723235591.96
時価総額 時価総額(百万ドル) 704.70290
売上高 売上高(百万ドル) 0.01600
企業価値(EV) 企業価値(EV)(百万ドル) 537.86790
当期純利益 当期純利益(百万ドル) -72.05600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Obseva SA revenues remained flat at $8K. Net loss increased 16% to $38M. Revenues reflect market conditions. Higher net loss reflects Research and Development Expenses - Bala increase of 14% to $25.6M (expense) General and Administrative Expenses - increase from $1.3M to $3M (expense) Staff Costs in R&D Expenses increase of 19% to $5.5M (expense).

 OBSVのテクニカル分析


 OBSVのニュース

   ObsEva down 42% on late-stage linzagolix data (NASDAQ:OBSV)  2020/07/06 15:29:21 Seeking Alpha
ObsEva SA (OBSV -41.8%) slumps on more than a 7x surge in volume on the heels of results from two Phase 3 clinical trials evaluating lead candidate linzago
   Livongo Health and Trevena among healthcare gainers; ObsEva among losers  2020/07/06 15:03:36 Seeking Alpha
Gainers: Trinity Biotech (NASDAQ:TRIB) +13%. Zynex (NASDAQ:ZYXI) +13%. Livongo Health (NASDAQ:LVGO) +12%. Trevena (NASDAQ:TRVN) +11%. Mesoblast MESO +11%.
   The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus  2020/07/06 12:08:57 Benzinga
Biotech stocks rebounded in the holiday-shortened week ending July 2 as investors reacted to pending clinical trial readouts and the news flow surrounding COVID-19 vaccine and treatment development. Australian biopharma Alterity Therapeutics Ltd (NASDAQ: ATHE ) was among the biggest gainers of the week after the company said it received FDA guidance for the Phase 2 study for its Parkinsonian disorder drug. Inovio Pharmaceuticals Inc (NASDAQ: INO ) and Pfizer Inc. (NYSE: PFE )/ BioNTech SE – ADR (NASDAQ: BNTX ) were among the companies that issued updates on their coronavirus vaccine programs. The week also saw FDA issuing guidance on the approval of COVID-19 vaccines, with the agency suggesting a vaccine needs to demonstrate at least 50% efficacy in a placebo-controlled trial. The following are key catalysts for the unfolding … Full story available on Benzinga.com
   ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids  2020/07/06 05:00:00 GlobeNewswire
PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24 PRIMROSE 2…
   ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020  2020/07/03 05:00:00 GlobeNewswire
Geneva, Switzerland and Boston, MA – July 3, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing…
   ObsEva down 42% on late-stage linzagolix data (NASDAQ:OBSV)  2020/07/06 15:29:21 Seeking Alpha
ObsEva SA (OBSV -41.8%) slumps on more than a 7x surge in volume on the heels of results from two Phase 3 clinical trials evaluating lead candidate linzago
   Livongo Health and Trevena among healthcare gainers; ObsEva among losers  2020/07/06 15:03:36 Seeking Alpha
Gainers: Trinity Biotech (NASDAQ:TRIB) +13%. Zynex (NASDAQ:ZYXI) +13%. Livongo Health (NASDAQ:LVGO) +12%. Trevena (NASDAQ:TRVN) +11%. Mesoblast MESO +11%.
   The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In Focus  2020/07/06 12:08:57 Benzinga
Biotech stocks rebounded in the holiday-shortened week ending July 2 as investors reacted to pending clinical trial readouts and the news flow surrounding COVID-19 vaccine and treatment development. Australian biopharma Alterity Therapeutics Ltd (NASDAQ: ATHE ) was among the biggest gainers of the week after the company said it received FDA guidance for the Phase 2 study for its Parkinsonian disorder drug. Inovio Pharmaceuticals Inc (NASDAQ: INO ) and Pfizer Inc. (NYSE: PFE )/ BioNTech SE – ADR (NASDAQ: BNTX ) were among the companies that issued updates on their coronavirus vaccine programs. The week also saw FDA issuing guidance on the approval of COVID-19 vaccines, with the agency suggesting a vaccine needs to demonstrate at least 50% efficacy in a placebo-controlled trial. The following are key catalysts for the unfolding … Full story available on Benzinga.com
   ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids  2020/07/06 05:00:00 GlobeNewswire
PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24 PRIMROSE 2…
   ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020  2020/07/03 05:00:00 GlobeNewswire
Geneva, Switzerland and Boston, MA – July 3, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing…
   How ObsEva (OBSV) Stock Stands Out in a Strong Industry  2020/04/23 12:45:00 Zacks Investment Research
ObsEva (OBSV) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.
   ObsEva and Selecta Bio up premarket on bullish ratings  2020/01/29 12:04:04 Seeking Alpha
ObsEva (NASDAQ:OBSV) initiated with Buy rating and $19 (395% upside) price target at Kempen & Co. Shares up 8% premarket. Selecta Biosciences (NASDAQ:SELB)
   ObsEva's Menstrual Bleeding Drug Produces 'Best-In-Class' Response In Late-Stage Study  2019/12/09 16:53:16 Benzinga Feeds
Swiss biopharma Obseva SA (NASDAQ: OBSV ), which is developing orally administered, clinical-stage compounds to treat women's reproductive health conditions, announced a positive late-stage clinical readout Monday for its investigational compound to treat heavy menstrual bleeding due to uterine fibroids. ObsEva saw its shares a decline steeply in early November due to a failed trial of nolasiban, another pipeline asset. ObsEva's Study Results The Phase 3 study dubbed PRIMROSE 2 met the primary and secondary efficacy endpoints, ObsEva said. The study evaluated once-daily oral linzagolix in 100mg and 200mg doses, with and without hormonal add-back therapy, or ABT, The primary efficacy endpoint was the reduction in heavy menstrual bleeding. The responder rate was 93.9% for women receiving 200mg linzagolix with ABT and 56.7% for women receiving 100mg without ABT versus 29.4% for the placebo group. The company termed the response for the 200mg dose as "best-in-class." Both doses achieved significant rates of amenorrhea, reduction …
   ObsEva Enters Oversold Territory  2019/11/15 15:47:00 Zacks Investment Research
ObsEva SA has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
   The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval  2019/11/15 12:08:29 Benzinga Feeds
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Castle Biosciences Inc (NASDAQ: CSTL ) China Biologic Products Holdings Inc (NASDAQ: CBPO )(reacted to its third-quarter results) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(priced its debt offering) IGM Biosciences Inc (NASDAQ: IGMS ) Kodiak Sciences Inc (NASDAQ: KOD ) Novo Nordisk A/S (NYSE: NVO ) Seattle Genetics, Inc. (NASDAQ: SGEN ) XOMA Corp (NASDAQ: XOMA ) XBiotech Inc (NASDAQ: XBIT ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 14) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Altimmune Inc (NASDAQ: ALT ) (reacted to its third-quarter results) Auris Medical Holding Ltd (NASDAQ: EARS ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) (priced its common stock offering) Cellectar Biosciences Inc (NASDAQ: CLRB ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オブスイヴァ OBSV ObsEva SA)

 twitter  (公式ツイッターやCEOツイッターなど)